Navigation Links
Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
Date:11/12/2007

ey are taking Kineret(R) to treat RA. ORENCIA should not be taken with Kineret. People taking ORENCIA should notify their doctor if they are taking any other medications including hormones, over-the-counter medicines, vitamins, supplements or herbal products.

Individuals should let their doctor know if they have any kind of infection including an infection that is in only one place of the body (such as an open cut or sore) or an infection that is in the whole body (such as the flu). Having an infection could increase the risk for serious side effects from ORENCIA(R) (abatacept). It is also important for individuals to let their doctor know if they have an infection that won't go away or a history of infections that keep coming back.

People who have had tuberculosis (TB), a positive skin test for TB, recent close contact with someone who has had TB or develop any of the symptoms of TB (a dry cough that doesn't go away, weight loss, fever, night sweats) should call their doctor right away. Before starting treatment with ORENCIA, a doctor may examine the individual for TB or perform a skin test.

In addition, individuals should let their doctor know if they are scheduled to have surgery or any vaccination or have recently received a vaccination. People should inform their doctor if they have a history of chronic obstructive pulmonary (lung) disease (COPD). Taking ORENCIA may cause COPD symptoms to get worse.

People who have diabetes and use a blood glucose monitor to check their sugar levels should tell their doctor. The infusion of ORENCIA contains maltose, a sugar that can give falsely high blood glucose readings with some monitors on the day the infusion is received. The doctor may recommend a different monitor.

Women who are pregnant, planning to become pregnant or are thinking about becoming pregnant should tell their doctor. It is not known if ORENCIA can harm an unborn baby. Women who are breast feeding should also inform their docto
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
2. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
3. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
4. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
5. ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
11. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... Future Prospects for Companies in Antihistamines, Corticosteroids, ... - new study showing you trends, partnerships, and ... allergic rhinitis drugs heading? What are the commercial prospects ... you potential revenues and other trends to 2025, discussing ... report provides 273 tables, charts, and graphs. Discover the ...
(Date:9/4/2015)... , Sep. 04, 2015 ... of the "Investigation Report on China,s Sodium Ibandronate Market, ... and used in the clinic under the trade name of ... Austria in 1996, sodium ibandronate was approved by ... treatment of osteoporosis under the trade name of Boniva. However, ...
(Date:9/4/2015)... September 4, 2015 Hutchison ... that Hutchison MediPharma Limited ("HMP"), its drug R&D ... second proof-of-concept ("POC") trial of fruquintinib in patients ... in China .  The top-line ... meeting the primary efficacy endpoint of progression free ...
Breaking Medicine Technology:Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Investigation Report on China's Sodium Ibandronate Market 2010-2019 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3
... Late Stage Clinical Therapeutic Cancer... -- TUEBINGEN, Germany, September 21, 2010 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... Inc., today announced that it reported positive preclinical ... Association for the Study of Diabetes (EASD).  CCX140, ... the chemokine receptor CCR2, improved metabolic function while ... in an animal model, and was well tolerated ...
Cached Medicine Technology:immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 2immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 3immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 4immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 5immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 6immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 7immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 8immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 9immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 10ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 2ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 3ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 4
(Date:9/4/2015)... AZ (PRWEB) , ... September 05, 2015 , ... ... Artists from China for an exclusive, one-night exhibition of their work at Paradise Valley ... exhibit on Friday, September 18, from 6-9 pm. The artists will be on hand ...
(Date:9/4/2015)... CA (PRWEB) , ... September 04, 2015 , ... According ... has been developed that changes color when subjected to an impact force that is ... could be implemented in helmets or other sporting equipment so that coaches or officials ...
(Date:9/4/2015)... ... 2015 , ... On the heels of highly successful events ... its annual health tech innovation program. Now featuring a two-phase health tech competition ... cash and prizes to advance their technologies toward commercialization, the newly expanded program ...
(Date:9/4/2015)... ... September 04, 2015 , ... Mile High Connects today releases “First ... lack of funding for sidewalks, bike paths, and other vital supports severely limit access ... region spends billions of dollars to expand public transit, there’s very little support for ...
(Date:9/4/2015)... ... 04, 2015 , ... The Providence Fertility Center will host a Fertility Cocktail ... egg freezing. , Date and Time: October 8, 2015 at Waterman Grille restaurant and ... informative event will discuss the basics of female fertility and egg freezing, and offer ...
Breaking Medicine News(10 mins):Health News:Paradise Valley Community College Announces Master Ceramic Artists & Exhibit 2Health News:New Article on Head Injury Detection Technology Highlights Implications for Head Injury Detection in Sports, says The Law Offices of Burg & Brock 2Health News:Insight Product Development Startup Competition on Track to Double Program Impact 2Health News:Insight Product Development Startup Competition on Track to Double Program Impact 3Health News:Missed Connections in Metro Denver Transit 2Health News:The Providence Fertility Center to Host Fertility Cocktail Hour on October 8, 2015 at Waterman Grille for Women Who Wish to Learn About Their Fertility and Egg Freezing 2
... In an effort to reach out to,wounded soldiers, Retired ... a series of uplifting and rejuvenating weekend,retreats -- offered ... trips,focus on rest and relaxation for soldiers hurt in ... combat with Islamic Terrorists,these brave men and women are ...
... A new medication that researchers had hoped ... stenting has turned in a disappointing performance in ... that was used to deliver the drug is ... was expected to reduce arterial inflammation and, therefore, ...
... Percutaneous coronary intervention (PCI) may be a reasonable alternative ... left main coronary artery, according to a study that ... stents and bypass surgery were used to restore blood ... treated with stenting were more likely to need a ...
... - Response Biomedical,Corporation (TSX: RBM, OTCBB: RPBIF) reported ... net loss of $13,901,041 or ($0.12) per share,for ... Company announced,that as of December 31, 2007 it ... further discussion of the Company,s financial results for,the ...
... Pharmaceutical Holdings, Inc. (Amex: KUN ) ("China ... research, development, manufacture,and marketing of pharmaceutical, nutritional supplement ... ("PRC"), today announced it will,conduct a conference call ... 2008, to,discuss the Company,s financial results for the ...
... NMHC,s Stockholders Accept ... SXC,s ... -,SXC Health Solutions Corp. ("SXC") (Nasdaq: SXCI ; TSX: SXC) ... jointly announced,today that, pursuant to their previously announced merger agreement, SXC ...
Cached Medicine News:Health News:Healing Wounds and Hearts: Warrior Weekend Helps Soldiers Relax and Recover 2Health News:Investigational anti-restenosis drug pimecrolimus disappoints 2Health News:Investigational anti-restenosis drug pimecrolimus disappoints 3Health News:Study finds support for PCI in unprotected left main disease 2Health News:Study finds support for PCI in unprotected left main disease 3Health News:Response Biomedical Corporation Reports 2007 Financial Results 2Health News:Response Biomedical Corporation Reports 2007 Financial Results 3Health News:Response Biomedical Corporation Reports 2007 Financial Results 4Health News:Response Biomedical Corporation Reports 2007 Financial Results 5Health News:China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results 2Health News:China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results 3Health News:SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc. 2Health News:SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc. 3Health News:SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc. 4Health News:SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc. 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: